GlassScriptPhysician profile
Sarah Bratcher
NPI 1881074433
$2,191.87
in general payments reported to CMS, 2019-2025
23 companies · $397 in 2025
The $397 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $161 · 2020: $170 · 2021: $140 · 2022: $369 · 2023: $279 · 2024: $675 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,352.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $557.11 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $374.71 | 2019-2024 | Jornay Pm |
| Pfizer INC. | $267.13 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $182.46 | 2025 | Jornay Pm |
| Sobi, INC | $161.05 | 2019-2023 | |
| Glaxosmithkline, LLC. | $130.71 | 2022-2024 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $73.01 | 2020-2022 | |
| Tris Pharma INC | $64.95 | 2020-2025 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $58.37 | 2022-2024 | Vaxneuvance, M-M-R II, Vaxelis |
| Corium, LLC | $41.01 | 2022 | |
| Seqirus USA INC | $37.13 | 2022-2023 | Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $32.39 | 2023-2024 | |
| Sanofi Pasteur INC. | $31.72 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $27.16 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $24.73 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $18.59 | 2019 | |
| Adlon Therapeutics L.P. | $17.48 | 2021 | |
| Cranial Technologies, INC | $16.97 | 2025 | Doc Band |
| Verrica Pharmaceuticals INC. | $16.70 | 2025 | Ycanth |
| Neos Therapeutics, LP | $15.25 | 2019 | |
| Nestle Healthcare Nutrition INC. | $15.18 | 2023 | |
| Avion Pharmaceuticals | $14.44 | 2023 | Methylphenidate Hydrochloride |
| Vertical Pharmaceuticals, LLC | $13.62 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Bratcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.